Background: Atrial Fibrillation (AF) has become a major global health concern and is associated
with an increased risk of poor outcomes. Identifying risk factors in patients with AF can be challenging, given
the high burden of comorbidities in these patients. Risk stratification schemes appear to facilitate accurate prediction
of outcomes and assist therapeutic management decisions.
Objective: To summarize current evidence on risk stratification scores for patients with AF.
Results: Traditional risk models rely heavily on demographics and comorbidities, while newer tools have been
gradually focusing on novel biomarkers and diagnostic imaging to facilitate more personalized risk assessment.
Several studies have been conducted to compare existing risk schemes and identify specific patient populations
in which the prognostic ability of each scheme excels. However, current guidelines do not appear to encourage
the implementation of risk models in clinical practice, as they have not incorporated new ones in their recommendations
for the management of patients with AF for almost a decade.
Conclusion: Further work is warranted to analyze new reliable risk stratification schemes and optimally implement
them into routine clinical life.